References
- Lazarou J , PomeranzBH, CoreyPN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA279(15) , 1200–1205 (1998).
- Teft WA , GongIY, DingleB et al. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res. Treat.139(1) , 95–105 (2013).
- Hoskins JM , CareyLA, McLeodHL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer9(8) , 576–586 (2009).
- Murdter TE , SchrothW, Bacchus-GerybadzeL et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89(5) , 708–717 (2011).
- Madlensky L , NatarajanL, TchuS et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89(5) , 718–725 (2011).
- Gong IY , TeftWA, LyJ et al. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Res. Treat. 139(1) , 61–69 (2013).
- Jin Y , DestaZ, StearnsV et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst.97(1) , 30–39 (2005).
- Goetz MP , SumanVJ, HoskinTL et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin. Cancer Res.19(2) , 500–507 (2013).
- Wang D , GuoY, WrightonSA, CookeGE, SadeeW. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4) , 274–286 (2011).
- Binkhorst L , van Gelder T, Loos WJ et al. Effects of CYP induction by rifampicin on tamoxifen exposure. Clin. Pharmacol. Ther.92(1) , 62–67 (2012).
- Lindh JD , AnderssonML, EliassonE, Bjorkhem-BergmanL. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metab. Dispos.39(5) , 933–937 (2011).
- Schwartz JB . Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin. Pharmacol. Ther.85(2) , 198–203 (2009).
- Moan J , PorojnicuAC, DahlbackA, SetlowRB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc. Natl Acad. Sci. USA105(2) , 668–673 (2008).
- Hadji P , AaproMS, BodyJJ et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann. Oncol. 22(12) , 2546–2555 (2011).
- Grant WB , CrossHS, GarlandCF et al. Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog. Biophys. Mol. Biol. 99(2–3) , 104–113 (2009).
- Goodwin PJ , EnnisM, PritchardKI, KooJ, HoodN. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol.27(23) , 3757–3763 (2009).
- Vrieling A , HeinR, AbbasS, SchneeweissA, Flesch-JanysD, Chang-ClaudeJ. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res.13(4) , R74 (2011).
- Irvin WJ , WalkoCM, WeckKE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29(24) , 3232–3239 (2011).
- Thummel KE , BrimerC, YasudaK et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol. Pharmacol. 60(6) , 1399–1406 (2001).
- Thirumaran RK , LambaJK, KimRB et al. Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem. Pharmacol. 84(1) , 104–112 (2012).